# Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

> **NCT04781816** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 78 (actual)

## Conditions studied

- Cutaneous Lupus Erythematosus

## Interventions

- **DRUG:** SAR443122
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04781816
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2023-05-25
- **Final completion:** 2023-06-26
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781816, "Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04781816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*